NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Prothena Corporation Public Limited Company PRTA
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.7M
▼ 92.8% vs FY2024
EPS · FY25
$-4.53
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-63.6%
Net margin · FY25
-2520.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.7M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 2521 cents on every revenue dollar this year.
Per share
USD -4.53
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-63.6%
Return on equity, FY2025
ROE
Operating margin-2216.4%
Net margin-2520.6%
Return on assets-55.9%
Each USD of equity lost 64 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+62.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−43.6%
+62.6%
+19.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+34.8%
Change, 10 years+69.6%
The share count grew 35% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 326.8M
total assets, end of FY2025
Total assetsUSD 326.8M
EquityUSD 280.5M
CashUSD 307.5M
Current ratio7.72×
Equity funds 86% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.1
0.1
0.1
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
·
Operating income $B
−0.2
−0.2
−0.2
−0.1
0.1
−0.1
−0.1
−0.2
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.1
0.1
−0.1
−0.1
−0.2
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.1
−0.1
−0.1
0.1
−0.1
−0.1
−0.2
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.53
−2.27
−2.76
−2.47
1.38
−2.78
−1.95
−3.93
−4.07
−4.66
−2.66
−0.29
−2.20
−2.84
−2.05
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−63.6
−23.3
−24.8
−21.5
20.6
−48.6
−26.1
−42.6
−39.7
−44.1
−24.8
−3.1
−27.4
−32.7
·
Shares out B
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed